Melissa Baird Sells 67,687 Shares of Hims & Hers Health, Inc. (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS) COO Melissa Baird sold 67,687 shares of Hims & Hers Health stock in a transaction on Wednesday, March 26th. The stock was sold at an average price of $34.84, for a total transaction of $2,358,215.08. Following the completion of the transaction, the chief operating officer now directly owns 751,243 shares of the company’s stock, valued at $26,173,306.12. The trade was a 8.27 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Melissa Baird also recently made the following trade(s):

• On Wednesday, February 12th, Melissa Baird sold 67,687 shares of Hims & Hers Health stock. The stock was sold at an average price of $44.71, for a total transaction of $3,026,285.77.
• On Tuesday, January 21st, Melissa Baird sold 67,687 shares of Hims & Hers Health stock. The shares were sold at an average price of $29.35, for a total value of $1,986,613.45.

Hims & Hers Health Price Performance

Shares of HIMS traded down $1.40 during mid-day trading on Thursday, reaching $31.96. 15,194,343 shares of the company’s stock were exchanged, compared to its average volume of 13,990,192. The business’s fifty day simple moving average is $39.77 and its 200-day simple moving average is $29.25. The stock has a market capitalization of $7.10 billion, a PE ratio of 72.63 and a beta of 1.37. Hims & Hers Health, Inc. has a 52-week low of $11.20 and a 52-week high of $72.98.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings data on Monday, February 24th. The company reported $0.11 earnings per share for the quarter, topping analysts’ consensus estimates of $0.09 by $0.02. The company had revenue of $481.14 million during the quarter, compared to analysts’ expectations of $494.56 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. Equities research analysts predict that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Institutional Investors Weigh In On Hims & Hers Health

Institutional investors have recently modified their holdings of the company. SlateStone Wealth LLC increased its position in shares of Hims & Hers Health by 4.0% in the fourth quarter. SlateStone Wealth LLC now owns 10,640 shares of the company’s stock valued at $257,000 after buying an additional 413 shares in the last quarter. Blume Capital Management Inc. grew its stake in Hims & Hers Health by 100.0% in the 4th quarter. Blume Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after acquiring an additional 600 shares during the last quarter. Summit Investment Advisors Inc. increased its holdings in Hims & Hers Health by 3.3% during the 4th quarter. Summit Investment Advisors Inc. now owns 19,853 shares of the company’s stock valued at $480,000 after acquiring an additional 628 shares in the last quarter. Cim LLC raised its position in Hims & Hers Health by 1.0% during the fourth quarter. Cim LLC now owns 71,869 shares of the company’s stock worth $1,738,000 after acquiring an additional 694 shares during the last quarter. Finally, Quest Partners LLC raised its position in Hims & Hers Health by 22.6% during the third quarter. Quest Partners LLC now owns 4,373 shares of the company’s stock worth $81,000 after acquiring an additional 807 shares during the last quarter. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the stock. BTIG Research started coverage on shares of Hims & Hers Health in a report on Tuesday, January 7th. They issued a “buy” rating and a $35.00 price target on the stock. Morgan Stanley downgraded shares of Hims & Hers Health from an “overweight” rating to an “equal weight” rating and upped their target price for the stock from $42.00 to $60.00 in a research note on Tuesday, February 18th. Bank of America lifted their price target on shares of Hims & Hers Health from $21.00 to $22.00 and gave the company an “underperform” rating in a research note on Tuesday, March 18th. Canaccord Genuity Group increased their price objective on Hims & Hers Health from $38.00 to $68.00 and gave the stock a “buy” rating in a research note on Wednesday, February 19th. Finally, Truist Financial raised their price objective on Hims & Hers Health from $24.00 to $39.00 and gave the stock a “hold” rating in a report on Wednesday, February 26th. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and six have issued a buy rating to the company. According to data from MarketBeat, Hims & Hers Health has an average rating of “Hold” and an average price target of $37.31.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.